Rethinking Expression To Accelerate Antibody Discovery

High-throughput discovery can return a large number of hits, yet functional testing needs soluble, correctly folded protein in quantities that traditional workflows cannot reliably deliver. For organizations running several campaigns in parallel, that gap constrains throughput and extends cycle times. Russell Coleman, Director, Strain Engineering at Primrose Bio, Inc., presents an approach that integrates the Pfenex Expression Technology platform directly into antibody screening.

The session looks at how higher quality and titer of enriched antibody fragments at screening scale, up to 10x more material, affects how many candidates reach lead-selection assays, and why the easiest molecules to produce are not the only ones worth advancing. It also considers what expression and developability insights can emerge during lead identification. Watch the presentation below to learn more.